Literature DB >> 16907844

Site-specific mutation of the interferon sensitivity-determining region (ISDR) modulates hepatitis C virus replication.

T Kohashi1, S Maekawa, N Sakamoto, M Kurosaki, H Watanabe, Y Tanabe, C-H Chen, N Kanazawa, M Nakagawa, S Kakinuma, T Yamashiro, Y Itsui, T Koyama, N Enomoto, M Watanabe.   

Abstract

The number of amino acid substitutions in the interferon sensitivity-determining region (ISDR) in the nonstructural 5A (NS5A) gene of hepatitis C virus (HCV) is closely associated with the interferon (IFN) response and viral load. Several HCV replicon-based studies have reported that ISDR sequences had an influence on viral replication in vitro. However, it is unclear as to how different ISDR sequences affect HCV replication. Various clinically observed ISDR sequences were introduced into HCV replicons and their contribution to viral replication was investigated using a colony formation assay and/or a transient replication assay. A mapping study of the ISDR was performed to identify the amino acid positions that critically affect replication. While no colonies were formed in the colony formation assay using HCV replicons with few mutations (0, 1 and 3) in the ISDR, numerous colonies (>200) appeared when using constructs with six mutations. Introduction of various distinct ISDR sequences with multiple mutations resulted in replication enhancement in transient assays. A mapping study identified several specific sites in the ISDR that critically affected replication, including codon 2209 which, in patients, was closely associated with a strong response to IFN. ISDR sequences associated with a clinical IFN response and viral load modulated the replication of HCV replicons, suggesting the importance of the ISDR sequence in HCV infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16907844     DOI: 10.1111/j.1365-2893.2006.00739.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  10 in total

1.  Novel cell culture-adapted genotype 2a hepatitis C virus infectious clone.

Authors:  Tomoko Date; Takanobu Kato; Junko Kato; Hitoshi Takahashi; Kenichi Morikawa; Daisuke Akazawa; Asako Murayama; Keiko Tanaka-Kaneko; Tetsutaro Sata; Yasuhito Tanaka; Masashi Mizokami; Takaji Wakita
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

2.  Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection.

Authors:  Mina Nakagawa; Naoya Sakamoto; Mayumi Ueyama; Kaoru Mogushi; Satoshi Nagaie; Yasuhiro Itsui; Seishin Azuma; Sei Kakinuma; Hiroshi Tanaka; Nobuyuki Enomoto; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2010-01-30       Impact factor: 7.527

3.  Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling.

Authors:  Kattareeya Kumthip; Pattranuch Chusri; Nikolaus Jilg; Lei Zhao; Dahlene N Fusco; Hong Zhao; Kaku Goto; Du Cheng; Esperance A Schaefer; Leiliang Zhang; Chansom Pantip; Satawat Thongsawat; Amornrat O'Brien; Lee F Peng; Niwat Maneekarn; Raymond T Chung; Wenyu Lin
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

4.  Ethanol and reactive species increase basal sequence heterogeneity of hepatitis C virus and produce variants with reduced susceptibility to antivirals.

Authors:  Scott Seronello; Jessica Montanez; Kristen Presleigh; Miriam Barlow; Seung Bum Park; Jinah Choi
Journal:  PLoS One       Date:  2011-11-08       Impact factor: 3.240

5.  Amino Acid Polymorphisms Within the Entire HCV NS5A Region in Estonian Chronic HCV 1b Patients With Different Treatment Response.

Authors:  Tatiana Kuznetsova; Tatjana Tallo; Vadim Brjalin; Irina Reshetnjak; Riina Salupere; Ljudmilla Priimagi; Olga Katargina; Maria Smirnova; Juris Jansons; Valentina Tefanova
Journal:  Hepat Mon       Date:  2013-12-14       Impact factor: 0.660

6.  In-Vitro Transcription analysis of NS5A from HCV-3a circulating in Pakistani patients with chronic hepatitis C and their differential response to antiviral therapy.

Authors:  Shameem Bhatti; Sobia Manzoor; Fahed Parvaiz; Javed Ashraf; Farakh Javed
Journal:  Pak J Med Sci       Date:  2017 Sep-Oct       Impact factor: 1.088

7.  Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.

Authors:  P Muñoz de Rueda; J Casado; R Patón; D Quintero; A Palacios; A Gila; R Quiles; J León; A Ruiz-Extremera; J Salmerón
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

8.  Overcoming hurdles in hepatitis C virus research: efficient production of infectious virus in cell culture.

Authors:  Erica Silberstein; Deborah R Taylor
Journal:  Int J Biomed Sci       Date:  2008-06

9.  Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy.

Authors:  Nathan A Cannon; Maureen J Donlin; Xiaofeng Fan; Rajeev Aurora; John E Tavis
Journal:  PLoS One       Date:  2008-05-07       Impact factor: 3.240

10.  The Association of Substitutions in the Hepatitis C Virus Subtype 1b Core Gene and IL28B Polymorphisms With the Response to Peg-IFNα-2a/RBV Combination Therapy in Azerbaijani Patients.

Authors:  Farah Bokharaei-Salim; Mostafa Salehi-Vaziri; Farzin Sadeghi; Maryam Esghaei; Seyed Hamidreza Monavari; Seyed Moayed Alavian; Shahin Fakhim; Hossein Keyvani
Journal:  Hepat Mon       Date:  2016-04-23       Impact factor: 0.660

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.